Nucleic acid molecules encoding for BACE1 antibodies

Patent metadata

Field	Value
Publication number	US-9879094-B2
Application number	US-201615234649-A
Country	US
Kind code	B2
Filing date	Aug 11, 2016
Priority date	Nov 10, 2010
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

The invention provides antibodies to specific neural proteins and methods of using the same.

First claim

What is claimed is:

1. A nucleic acid encoding a heavy chain, or both a heavy chain and a light chain, of an antibody or fragment thereof that binds to β-site amyloid precursor protein cleaving enzyme 1 (BACE1), wherein the antibody or fragment thereof comprises:
a) a hypervariable region (HVR)-H1 comprising the amino acid sequence GFTFX 13 GYX 14 IH (SEQ ID NO:26), wherein X 13 =S or L and X 14 =A or G;
b) an HVR-H2 comprising the amino acid sequence GWISPAGGSTDYADSVKG (SEQ ID NO: 24);
c) an HVR-H3 comprising the amino acid sequence of GPFSPWVMDY (SEQ ID NO: 25),
d) an HVR-L1 comprising the amino acid sequence of RASQX 1 VX 2 X 3 X 4 X 5 A (SEQ ID NO:17), wherein X 1 =D or V; X 2 =S or A; X 3 =T or N; X 4 =S or A; X 5 =V or L;
e) an HVR-L2 comprising the amino acid sequence of X 6 ASFLYS (SEQ ID NO:18) wherein X 6 =S or L; and
f) an HVR-L3 comprising the amino acid sequence of QQX 7 X 8 X 9 X 10 X 11 X 12 T (SEQ ID NO:19), wherein X 7 =S, F, G, D or Y; X 8 =Y, P, S, or A; X 9 =T or N; X 10 =T, Y, D or S; X 11 =P or L; X 12 =P or T;

wherein the antibody reduces or inhibits the activity of BACE1.

2. The nucleic acid of claim 1 , wherein the nucleic acid encodes a heavy chain of the antibody.

3. The nucleic acid of claim 1 , wherein the nucleic acid encodes the heavy chain and the light chain of the antibody.

4. The nucleic acid of claim 1 , wherein the HVR-H1 comprises an amino acid sequence selected from SEQ ID NO:22 and SEQ ID NO:23.

5. The nucleic acid of claim 2 , wherein the HVR-H1 comprises an amino acid sequence selected from SEQ ID NO:22 and SEQ ID NO:23.

6. The nucleic acid of claim 3 , wherein the HVR-H1 comprises an amino acid sequence selected from SEQ ID NO:22 and SEQ ID NO:23.

7. The nucleic acid of claim 1 , wherein the antibody comprises a VH chain having an amino acid sequence selected from SEQ ID NOs: 20 and 21.

8. The nucleic acid of claim 2 , wherein the antibody comprises a VH chain having an amino acid sequence selected from SEQ ID NOs: 20 and 21.

9. The nucleic acid of claim 3 , wherein the antibody comprises a VH chain having an amino acid sequence selected from SEQ ID NOs: 20 and 21.

10. The nucleic acid of claim 3 , wherein the HVR-L1 comprises the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:8; the HVR-L2 comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; and the HVR-L3 comprises an amino acid sequence selected from SEQ ID NOs:11-16.

11. The nucleic acid of claim 3 , wherein the antibody comprises a VL chain sequence having an amino acid sequence selected from SEQ ID NOs: 1-6.

12. The nucleic acid of claim 3 , wherein the HVR-H1 comprises the amino acid sequence selected of SEQ ID NO:23, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:7, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:9 and the HVR-L3 comprises the amino acid sequence of SEQ ID NO:12.

13. The nucleic acid of claim 3 , wherein the antibody comprises a VH chain having an amino acid sequence selected from SEQ ID NOs: 20 and 21, and a VL chain sequence having an amino acid sequence selected from SEQ ID NOs: 1-6.

14. The nucleic acid of claim 3 , wherein the antibody comprises a VH chain having the amino acid sequence of SEQ ID NO: 21 and a VL chain sequence having the amino acid sequence of SEQ ID NO: 2.

15. A host cell comprising the nucleic acid of claim 1 .

16. A host cell comprising the nucleic acid of claim 3 .

17. A host cell comprising a first nucleic acid and a second nucleic acid, wherein the first nucleic acid encodes the heavy chain of an antibody or fragment thereof and the second nucleic acid encodes the light chain of an antibody or fragment thereof, wherein the antibody or fragment thereof binds to n-site amyloid precursor protein cleaving enzyme 1 (BACE1); and wherein the antibody or fragment thereof comprises:
a) a hypervariable region (HVR)-H1 comprising the amino acid sequence GFTFX 13 GYX 14 IH (SEQ ID NO:26), wherein X 13 =S or L and X 14 =A or G;
b) an HVR-H2 comprising the amino acid sequence GWISPAGGSTDYADSVKG (SEQ ID NO: 24);
c) an HVR-H3 comprising the amino acid sequence of GPFSPWVMDY (SEQ ID NO: 25),
d) an HVR-L1 comprising the amino acid sequence of RASQX 1 VX 2 X 3 X 4 X 5 A (SEQ ID NO:17), wherein X 1 =D or V; X 2 =S or A; X 3 =T or N; X 4 =S or A; X 5 =V or L;
e) an HVR-L2 comprising the amino acid sequence of X 6 ASFLYS (SEQ ID NO:18) wherein X 6 =S or L; and
f) an HVR-L3 comprising the amino acid sequence of QQX 7 X 8 X 9 X 10 X 11 X 12 T (SEQ ID NO:19), wherein X 7 =S, F, G, D or Y; X 8 =Y, P, S, or A; X 9 =T or N; X 10 =T, Y, D or S; X 11 =P or L; X 12 =P or T;

wherein the antibody reduces or inhibits the activity of BACE1.

18. The host cell of claim 16 , wherein the HVR-H1 comprises the amino acid sequence selected of SEQ ID NO:23, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:7, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:9 and the HVR-L3 comprises the amino acid sequence of SEQ ID NO:12.

19. The host cell of claim 17 , wherein the HVR-H1 comprises the amino acid sequence selected of SEQ ID NO:23, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:7, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:9 and the HVR-L3 comprises the amino acid sequence of SEQ ID NO:12.

20. The host cell of claim 16 , wherein the antibody comprises a VH chain having an amino acid sequence selected from SEQ ID NOs: 20 and 21, and a VL chain sequence having an amino acid sequence selected from SEQ ID NOs: 1-6.

21. The host cell of claim 17 , wherein the antibody comprises a VH chain having an amino acid sequence selected from SEQ ID NOs: 20 and 21, and a VL chain sequence having an amino acid sequence selected from SEQ ID NOs: 1-6.

22. The host cell of claim 16 , wherein the antibody comprises a VH chain having the amino acid sequence of SEQ ID NO: 21 and a VL chain sequence having the amino acid sequence of SEQ ID NO: 2.

23. The host cell of claim 17 , wherein the antibody comprises a VH chain having the amino acid sequence of SEQ ID NO: 21 and a VL chain sequence having the amino acid sequence of SEQ ID NO: 2.

24. A method of producing an antibody comprising culturing the host cell of claim 16 so that the antibody is produced.

25. A method of producing an antibody comprising culturing the host cell of claim 17 so that the antibody is produced.

26. A nucleic acid encoding a light chain of an antibody or fragment thereof that binds to β-site amyloid precursor protein cleaving enzyme 1 (BACE1), wherein the antibody or fragment thereof comprises:
a) an HVR-L1 comprising an amino acid sequence of SEQ ID NO:7 or SEQ ID NO:8; and
b) an HVR-L2 comprising an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; and
c) an HVR-L3 comprising an amino acid sequence selected from SEQ ID NOs:12-16.

27. The nucleic acid molecule of claim 26 , wherein the antibody comprises a VL chain sequence having an amino acid sequence selected from SEQ ID NOs: 2-6.

Assignees

• Genentech Inc

Inventors

• Atwal Jasvinder
• Chen Yongmei
• Chiu Cecilia Pui Chi
• Lazarus Robert A
• Wang Weiru
• Watts Ryan J
• Wu Yan
• Zhang Yingnan

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title